Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics (TNGX) announced significant developments, including the Fast Track Designation for its lead candidate, TNG908, an inhibitor targeting MTAP-deleted cancers. The company plans to start a Phase 1/2 clinical trial in Q2 2022, with preliminary data expected in H1 2023. Tango also reported financial results for 2021, revealing a net loss of $58.2 million and a revenue of $37 million. A strong cash position of $485 million is anticipated to support operations through the second half of 2024.
Tango Therapeutics (NASDAQ: TNGX) announced three abstracts selected for presentation at the AACR 2022 Annual Meeting, highlighting innovative cancer therapies. The presentations will cover:
- TNG908: an MTAP-null selective PRMT5 inhibitor showing tumor regressions in various cancer models.
- USP1 inhibitor: exploring synthetic lethality in BRCA1-mutant cancer via PCNA ubiquitination.
- UMIBB: introducing a Bayesian method enhancing CRISPR-Cas9 screen analysis.
These advancements aim to strengthen precision oncology and enrich Tango's therapeutic pipeline.
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced the presentation of an e-Poster at the 2022 ESMO Targeted Anticancer Therapies Congress, scheduled for March 7-8, 2022. The poster titled 'Evidence for synergy between TNG908, an MTAP-null selective PRMT5 inhibitor, and sotorasib in an MTAP-null/KRASG12C xenograft model' will be presented on March 4 at 12:00 CET. Tango focuses on developing precision cancer medicines based on synthetic lethality, targeting crucial cancer pathways.
Tango Therapeutics (NASDAQ: TNGX) has announced participation in two virtual investor conferences in February 2022. The Guggenheim 2022 Oncology Conference is scheduled for February 9 at 9:00 AM ET, followed by the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 1:00 PM ET. Live webcasts of these events will be available on the company's website, with replays accessible for 30 days post-event. Tango specializes in precision cancer medicines, employing innovative approaches to target cancer effectively.
Tango Therapeutics, a biotechnology company focused on precision cancer medicines, announced participation in two virtual investor conferences in February 2022. The Guggenheim 2022 Oncology Conference is scheduled for February 9, 2022, at 9:00 AM ET, while the 11th Annual SVB Leerink Global Healthcare Conference will take place on February 16, 2022, at 1:00 PM ET. Live webcasts will be available under the 'Events & Presentations' section on the company’s website, with replays accessible for 30 days.
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced the FDA's clearance of the IND for its lead program, TNG908, a selective PRMT5 inhibitor targeting cancers with MTAP deletions. The first-in-human clinical trial is expected to commence in 1H 2022, with preliminary data anticipated in 1H 2023. The company is also advancing its Target 3 program, aimed at reversing immune evasion in STK11 mutant cancers, and plans to develop a USP1 inhibitor for BRCA1-mutant cancers in 2H 2022. Tango’s cash balance is projected to fund operations into 2H 2024.
Tango Therapeutics (NASDAQ: TNGX) announced participation in the Jefferies London Healthcare Conference on November 18, 2021. The management team will present, with the session available on-demand starting at 8 AM GMT. A replay will be accessible for 30 days on the company's website. Tango focuses on precision cancer medicine, leveraging synthetic lethality to target cancer cells and enhance treatment efficacy. For more details, visit tangotx.com.
Tango Therapeutics (TNGX) reported a strong cash position of $504 million, ensuring funding for operations through 2024. The company is on track for an IND filing for TNG908, a PRMT5 inhibitor targeting cancers with MTAP deletion, expected in Q4 2021. Q3 2021 collaboration revenue rose to $6.8 million, a significant turnaround from a prior decline. R&D expenses increased to $21.9 million, while the net loss decreased to $19.6 million or $0.28 per share, down from $26.8 million previously.
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced two senior management appointments on November 1, 2021. Marc Rudoltz, M.D., joins as Chief Medical Officer, bringing over 20 years of oncology clinical development experience. Doug Barry, J.D., has been appointed General Counsel, with over 20 years in corporate law. CEO Barbara Weber expressed confidence in their expertise, particularly as Tango advances TNG908, a PRMT5 inhibitor, into clinical trials in 2022. Tango focuses on precision cancer medicine, leveraging synthetic lethality for novel treatment targets.
Tango Therapeutics (NASDAQ: TNGX) announced five abstracts selected for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The preclinical data emphasize the potential of synthetic lethal targeting in cancer treatment, particularly highlighting TNG908, a PRMT5 inhibitor showing significant regressions in MTAP-deleted cancers. Dr. Barbara Weber, CEO, will co-chair a session on synthetic lethality during the conference, underscoring Tango's commitment to advancing precision cancer therapies.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
